SCHEMBL23928233

SCHEMBL23928233

NCCc1ccc(NC(=O)CN2CCC(F)(F)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.52
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 3/20 0.50
THRB P10828 1/20 0.50
ATM Q13315 2/20 0.47
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
REV1 Q9UBZ9 2/20 0.46
USP2 O75604 1/20 0.45
NPC1 O15118 2/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
SIGMAR1 Q99720 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23963284 0.88 ALDH1A1 (0.50) ALDH1A1KDM4EATML3MBTL1MEN1
SCHEMBL23928147 0.85 KDM4E (0.64) HRH3ALDH1A1KDM4ETHRBHTT
SCHEMBL23928215 0.84 HRH3 (0.52) HRH3ALDH1A1KDM4ETHRBATM
SCHEMBL23928157 0.83 SMYD3 (0.53) HRH3ALDH1A1KDM4ETHRBATM
SCHEMBL23963222 0.82 LMNA (0.60) HRH3ALDH1A1KDM4EATML3MBTL1
SCHEMBL4218487 0.82 ATM (0.64) ALDH1A1ATMMEN1KMT2AREV1
SCHEMBL23963263 0.82 HRH3 (0.68) HRH3ALDH1A1KDM4EATMTDP1
SCHEMBL23291330 0.79 NAMPT (0.55) HRH3ALDH1A1KDM4ETHRBATM
SCHEMBL13149712 0.75 ALDH1A1 (0.53) HRH3ALDH1A1KDM4ETHRBTDP1
SCHEMBL13984140 0.74 HRH3 (0.49) HRH3ALDH1A1KDM4ETHRBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 HRH3 416/4885ALDH1A1 571/4885KDM4E 3952/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 HRH3 416/4885ALDH1A1 571/4885KDM4E 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.